Announcements Trials
Browse Landscape

Phase

Phase 2 21Phase 3 4Phase NA 2Phase 4 2Phase 1 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 2Lymphoid 2Gynecologic 2Breast 1

Conditions

Ovarian Neoplasms 2Neoplasms 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 10human papillomavirus vaccine, L1 type 16, 18 7olaparib 4niraparib 4Human Papillomavirus Recombinant Vaccine nonavalent 4Vaccines 3Saline Solution 3Papillomavirus Vaccines 3Medroxyprogesterone Acetate 3Carboplatin 3Bevacizumab 3pegylated granulocyte colony-stimulating factor 2liposomal doxorubicin 2fluciclovine F-18 2apatinib 2Sevoflurane 2Propofol 2Paclitaxel 2Aspirin 2semaglutide 1pegfilgrastim 1pazopanib 1palbociclib 1lenvatinib 1halofantrine 1ganirelix 1gadofosveset trisodium 1fosaprepitant 1follicle stimulating hormone, human, with HCG C-terminal peptide 1ferrous gluconate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × apatinib × Gynecologic × Clear all
NCT03475589 2020-05-12

Study on the Adverse Drug Reactions (ADRs) of Apatinib and Their Biomarker Correlations

Sun Yat-sen University

Phase 4 Unknown
217 enrolled
Gynecologic

Neoplasms, Ovarian Neoplasms

NCT03384511 2018-02-20

The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.

Shandong Cancer Hospital and Institute

Phase 4 Completed
38 enrolled
BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡